ESYA Labs, a global leader in lysosomal biology and biomarker discovery for neurodegenerative diseases, has announced a transformative partnership with Alamar Biosciences, a pioneer in ultra-sensitive immunoassay technologies. By merging their respective strengths, the collaboration aims to revolutionise the detection and quantification of biomarkers for neurological and inflammatory diseases, using Alamar’s NULISA platform and ARGO HT System. These advanced technologies will be made available through ESYA’s cutting-edge laboratory in Dallas, Texas.
“We are thrilled to partner with ESYA labs. The integration of Alamar’s novel NULISA biomarker assays into their multi-omics platform will advance the field of testing for neurodegeneration diseases.”
ESYA Labs will be a certified service provider for Alamar, delivering tailored assay solutions to support pharmaceutical companies in developing therapeutics for a broad range of neurological, inflammatory, and neurodegenerative conditions. These include Alzheimer’s, Parkinson’s, FTD, ALS, and other disorders affecting the central and peripheral nervous systems.
HealthTech Insights: Hyundai Supports UCI Health with Diabetes Donation
By combining ESYA’s advanced lysosomal biology insights and machine learning-driven diagnostics with Alamar’s ultra-sensitive immunoassay technology, the collaboration will enable the creation of robust, targeted solutions to support the next generation of precision medicine.
Dhivya Venkat, CEO of ESYA Labs, commented: “Our partnership with Alamar marks a milestone in our mission to redefine precision diagnostics. By integrating ESYA’s cutting-edge platforms with Alamar’s innovative assay systems, we’re poised to deliver transformative tools for addressing the challenges of neurodegenerative diseases.”
HealthTech Insights: HapTech Leads Audio Therapy Innovation in HealthTech
Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences, remarked: “We are thrilled to partner with ESYA labs. The integration of Alamar’s novel NULISA biomarker assays into their multi-omics platform will advance the field of testing for neurodegeneration diseases.”
The collaboration capitalises on ESYA’s expertise in multi-omics and computational analytics alongside Alamar’s revolutionary immunoassay capabilities, setting a new standard for assessing neurological conditions.
HealthTech Insights: LG AI Creates AWS-Based Model for Faster Cancer Diagnosis
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – Businesswire
